Ziprasidone

Schizophrenia

Ziprasidone is prescribed to treat the symptoms of schizophrenia. This condition can cause changes in thinking, feelings, and behavior, such as hearing voices or seeing things that are not there, feeling suspicious of others, or experiencing a loss of interest in daily activities.

Bipolar I Disorder

This medication is used to treat acute manic or mixed episodes associated with bipolar I disorder. These episodes are characterized by periods of:

• Abnormally high or irritable moods
• Racing thoughts
• Increased energy or activity
• Decreased need for sleep

Ziprasidone may be used alone for the short-term treatment of these episodes. It is also used as a long-term maintenance treatment for bipolar I disorder, typically when combined with other medications such as lithium or valproate, to help prevent future episodes from occurring.

Mechanism of Action

Ziprasidone belongs to a group of medicines called atypical antipsychotics. Although the exact way it works is not fully understood, researchers believe it helps treat symptoms of schizophrenia and bipolar disorder by changing the balance of neurotransmitters in the brain.

Neurotransmitters are natural chemical messengers that transmit signals between nerve cells. Ziprasidone primarily affects two key chemicals:

• Dopamine: It blocks certain dopamine receptors. Overactivity of dopamine in specific areas of the brain is thought to contribute to symptoms like hallucinations and delusions.
• Serotonin: It interacts with various serotonin receptors. This interaction is believed to help improve mood, cognitive function, and social behavior.

By modulating the activity of these chemicals, ziprasidone helps stabilize brain activity, which can reduce the severity of psychiatric symptoms and help prevent them from recurring.

Common Side Effects

• Drowsiness or fatigue
• Dizziness
• Nausea or vomiting
• Constipation or diarrhea
• Dry mouth
• Restlessness or an inability to sit still
• Muscle stiffness or tremors
• Vision changes
• Runny nose or cough

Serious Side Effects

Seek medical attention immediately if you experience any of the following:

• Fast, pounding, or irregular heartbeat
• Fainting or severe dizziness
• Fever, muscle rigidity, confusion, and sweating
• Uncontrolled muscle movements, especially in the face, tongue, or limbs
• Severe skin rash, which may be accompanied by fever and swollen lymph nodes
• Signs of high blood sugar, such as extreme thirst, frequent urination, or fruity-smelling breath
• Difficulty swallowing
• Seizures
• A painful or prolonged erection

Increased Mortality in Elderly Patients

Ziprasidone is not approved for the treatment of patients with dementia-related psychosis. Clinical trials have shown that elderly patients with dementia-related psychosis who are treated with antipsychotic drugs are at an increased risk of death compared to those receiving a placebo.

Heart Rhythm Changes (QT Prolongation)

Ziprasidone can cause a change in the heart's electrical activity known as QT prolongation. This condition can lead to a rare but life-threatening heart rhythm called Torsade de Pointes. Because of this risk, ziprasidone is contraindicated in individuals with:

• A history of long QT syndrome.
• A recent heart attack (acute myocardial infarction).
• Uncompensated heart failure.
• Certain heart rhythm disorders (arrhythmias).
• Concurrent use of other medications known to prolong the QT interval.

Healthcare providers may monitor electrolyte levels, such as potassium and magnesium, as imbalances can increase the risk of heart rhythm issues.

Severe Skin and Systemic Reactions

A rare but serious condition called Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) has been reported with ziprasidone use. This reaction may start as a rash but can progress to affect internal organs such as the liver, kidneys, or lungs. Immediate medical evaluation is necessary if a rash occurs in combination with fever or swollen lymph nodes.

Neuroleptic Malignant Syndrome (NMS)

NMS is a rare and potentially fatal reaction associated with antipsychotic medications. Symptoms include high fever, muscle rigidity, altered mental status, and evidence of autonomic instability, such as irregular pulse or blood pressure.

Tardive Dyskinesia

The use of ziprasidone may lead to tardive dyskinesia, a condition characterized by involuntary, repetitive movements, often involving the face, tongue, or jaw. The risk is believed to increase with the duration of treatment and the total cumulative dose, although it can develop after relatively brief treatment periods at low doses.

Metabolic Changes

Antipsychotic medications are associated with metabolic changes that may increase cardiovascular risk. These include:

• Hyperglycemia and Diabetes: Severe elevations in blood sugar have been reported. Patients with an existing diagnosis of diabetes or those at risk for diabetes should undergo regular glucose monitoring.
• Dyslipidemia: Changes in cholesterol and triglyceride levels may occur.
• Weight Gain: Significant weight gain has been observed in some patients.

Other Precautions

Ziprasidone may cause orthostatic hypotension, which is a sudden drop in blood pressure when standing up, leading to dizziness or fainting. It may also cause somnolence (drowsiness) that can impair the ability to perform tasks requiring mental alertness. Additionally, low white blood cell counts (leukopenia, neutropenia, and agranulocytosis) have been reported, and ziprasidone should be used with caution in patients with a history of seizures.

Pregnancy

There are no adequate and well-controlled studies of ziprasidone use in pregnant women. Healthcare providers typically only prescribe this medication during pregnancy if the potential benefit justifies the potential risk to the fetus.

Infants exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal or withdrawal symptoms after delivery. These symptoms may include:

• Agitation and tremors
• Increased or decreased muscle tone
• Sleepiness
• Difficulty breathing
• Feeding disorders

The severity of these symptoms can vary. Some newborns recover within hours or days without specific treatment, while others may require intensive care or prolonged hospitalization.

Patients who become pregnant while taking ziprasidone are encouraged to talk to their doctor about enrolling in a pregnancy exposure registry to monitor the health of both the parent and the baby.

Breastfeeding

It is not known whether ziprasidone is excreted in human breast milk. Because many drugs are passed through milk and the effects on the infant are unknown, it is generally recommended that women do not breastfeed while taking ziprasidone. Patients should discuss the risks and benefits of breastfeeding with their healthcare provider.

Available Forms

Ziprasidone is produced in two primary delivery methods:

• Oral Capsules: This form is taken by mouth and is generally used for long-term management.
• Intramuscular Injection: This form is administered by a healthcare professional into a muscle. It is typically used in clinical settings for the treatment of acute symptoms.

FDA Approval and Indications

Ziprasidone was first approved by the U.S. Food and Drug Administration (FDA) in 2001. It is indicated for the treatment of schizophrenia and the acute treatment of manic or mixed episodes associated with bipolar I disorder. It is also approved for maintenance treatment of bipolar I disorder when used alongside lithium or valproate.

Boxed Warning

Ziprasidone contains a boxed warning stating that elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. This medication is not FDA-approved for the treatment of patients with dementia-related psychosis.

Safety Communications

The FDA has issued safety communications regarding a rare but serious skin reaction known as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). This condition can begin as a rash and progress to affect internal organs; the FDA requires this risk to be documented on the drug's professional labeling.

Discontinuing Ziprasidone

It is important to continue taking ziprasidone even if you feel well. Do not stop taking this medication without talking to your healthcare provider first. Stopping the drug suddenly may cause your symptoms to return or worsen.

Managing the Transition

When it is time to stop treatment, a doctor will usually provide a schedule to gradually decrease the dose. This tapering process helps prevent a relapse of symptoms such as agitation, hallucinations, or mood instability.

Withdrawal Symptoms in Newborns

Infants born to individuals who took ziprasidone during the third trimester of pregnancy may experience withdrawal symptoms or extrapyramidal signs after delivery. These symptoms may include:

• Difficulty breathing or feeding
• Excessive sleepiness
• Muscle stiffness or tremors
• Irritability or agitation

If you are pregnant, do not stop taking your medication without medical advice, as untreated mental health conditions can also pose risks during pregnancy.